What kinds of comparable outcomes and end points are investigators documenting when comparing the reference molecule to a biosimilar agent?

What kinds of comparable outcomes and end points are investigators documenting when comparing the reference molecule to a biosimilar agent?

In general, what kinds of comparable outcomes and end points are investigators documenting for when comparing the reference molecule to a biosimilar agent that is being evaluated for similar disease states?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Joseph Markenson, MD

Joseph Markenson, MD

Department of Rheumatology
Department of Medicine
Hospital for Special Surgery, New York, NY
Attending Physician, Hospital for Special Surgery
Professor of Clinical Medicine, Weill Cornell Medical College